Christopher Peetz serves as the Chief Executive Officer of Mirum Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare and orphan diseases. With a robust background in the pharmaceutical industry, Peetz brings a wealth of experience and leadership to his role at Mirum. Prior to joining Mirum, he held the position of President at Aimmune Therapeutics, where he was instrumental in advancing the company's mission to address food allergies through innovative treatments. His tenure at Aimmune was marked by significant milestones, including the successful launch of Palforzia, the first FDA-approved treatment for peanut allergy. Before his role at Aimmune, Peetz spent over a decade at Genentech, where he held various leadership positions in commercial operations and strategy. His time at Genentech was characterized by his ability to drive growth and innovation within the company's diverse portfolio of biologic medicines. Peetz's strategic vision and deep understanding of the biopharmaceutical landscape have been pivotal in shaping Mirum's growth trajectory. Under his leadership, Mirum has made significant strides in advancing its pipeline of treatments, particularly in the areas of liver disease and other rare genetic disorders. As CEO of Mirum Pharmaceuticals, Peetz is responsible for overseeing the company's overall strategy and operations, with a keen focus on bringing life-changing therapies to patients with limited treatment options. His commitment to innovation and patient-centric care is evident in Mirum's ongoing efforts to develop and commercialize novel treatments. Peetz's leadership has been crucial in fostering a collaborative and dynamic environment at Mirum, positioning the company as a leader in the rare disease space. His dedication to advancing the field of medicine continues to drive Mirum's mission to transform the lives of patients around the world.